CDKN1B and prostate adenocarcinoma: For example, rAAV-based PTEN/CDKN1B delivery is promising for the development of novel therapeutics for PRAD because of its potential contribution [13], miR-338-3p may be a possible predictor of poor prognosis [14], some lncRNAs may be novel biomarkers in the diagnosis and prognosis of PRAD [15], and the lncRNA H19 regulates tumor plasticity in neuroendocrine prostate cancer [16].